Bacteroides eggerthii as a potential treatment strategy for MASLD and obesity
- 주제(키워드) Metabolic dysfunction-associated steatotic liver disease (MASLD) , gut microbiome , Obesity , 16S rRNA sequencing
- 주제(DDC) 570
- 발행기관 아주대학교 일반대학원
- 지도교수 김순선
- 발행년도 2025
- 학위수여년월 2025. 2
- 학위명 석사
- 학과 및 전공 일반대학원 의생명과학과
- 실제URI http://www.dcollection.net/handler/ajou/000000034651
- 본문언어 영어
- 저작권 아주대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
Background/Aim: The gut microbiome has been increasingly recognized as a key factor in the pathogenesis of Metabolic dysfunction-associated steatotic liver disease (MASLD), however the therapeutic potential of specific microbiota remains underexplored. This study aimed to investigate the effects of Bacteroides eggerthii on liver health, specifically focusing on MASLD progression, and to assess changes in the gut microbiome, gene expression, and metabolic profiles associated with this intervention. Methods: We identified the gut microbiome using 16s rRNA sequencing and metagenomic sequencing from the feces of subjects with and without MASLD. Male mice fed a western diet (WD) or WD supplemented with Bacteroides eggerthii (WD+B) for 12 weeks were compared with control diet-fed groups to evaluate liver pathology, serum biochemistry, and fecal metabolomics. Histological examination and multivariate statistical analysis were conducted to assess microbiome and metabolite changes across groups. Results: In the WD group, MASLD indicators such as liver weight, fat accumulation, and AST and ALT levels were significantly elevated compared to controls, with marked reductions observed in the WD+B group. Histopathological analyses revealed substantial improvements in inflammation and fibrosis in the WD+B group, aligning with improved NAFLD activity scores. Fecal metabolomic profiling identified 39 altered metabolites, with distinctive bile acid and lipid signatures that correlated with MASLD pathology. ROC analysis further highlighted specific metabolites as potential MASLD biomarkers. Conclusion: Bacteroides eggerthii demonstrated therapeutic effects on MASLD progression by modulating gut-liver axis pathways, supporting its potential as a microbiome-based strategy for MASLD prevention and treatment.
more목차
Ⅰ. INTRODUCTION 1
Ⅱ. MATERIALS AND METHODS 3
1. Patients 3
2. Stool analysis for the metagenomics 3
3. 16s rRNA ribosomal analysis 4
4. Correlation heatmap 4
5. Functional pathway analysis 4
6. Strain preparation 5
7. Animal experiments 5
8. Pathology analysis 6
9. Serum biochemistry analysis 7
10. RNA‐sequencing data analysis 7
11. GSEA (Gene Set Enrichment Analysis) 8
12. qRT-PCR (quantitative real-time polymerase chain reaction analysis) 8
13. Western blot 9
14. Metabolite extraction 10
15. Metabolome analysis 10
16. Network analysis 12
17. Statistical analysisintegrins 12
Ⅲ. RESULTS 14
1. Baseline characteristics of patients 14
2. Microbiome Analysis of N, MASLD, and OB Patients 16
3. Microbiome analysis of microbial communities and clinical characteristics in patients with N, MASLD, and OB 18
4. Changes in microbial communities among N, MASLD, and OB 20
5. Oral administration of Bacteroides eggerthii in the MASLD mouse model restores body weight, fat accumulation, and liver morphology 23
6. Oral administration of Bacteroides eggerthii alleviates damage to the liver in the MASLD mouse model 25
7. Changes in fecal microbiota composition among the ND, WD, and WD+B groups 27
8. LDA analysis for predicting functional changes following the oral administration of Bacteroides eggerthii 30
9. Bacteroides eggerthii modulates changes in RNA transcription in the liver 31
10. Bacteroides eggerthii alters genes related to fatty acid and bile acid metabolism 33
11. Metabolites altered by Bacteroides eggerthii and ROC analysis of these metabolites 36
12. Network analysis of microbial and metabolite correlations Altered by Bacteroides eggerthii treatment 38
Ⅳ. DISCUSSION 40
Ⅴ. REFERENCES 44
국문 요약 50
